Malignant hyperthermia in Poland: A survey study.

Area of Science:

• Anesthesiology
• Pharmacology
• Medical Genetics

Background:

• Malignant hyperthermia (MH) is a critical pharmacogenetic disorder triggered by anesthetics.
• The incidence of MH varies globally, but is unknown in Poland due to reporting gaps.
• Dantrolene, the primary treatment for MH, faces accessibility challenges in Poland.

Purpose of the Study:

• To determine the prevalence of malignant hyperthermia in Poland.
• To assess the availability and accessibility of dantrolene in Polish healthcare facilities.

Main Methods:

• A nationwide questionnaire survey of anesthesia and intensive care unit chiefs in Poland.
• Data collection covered reported MH episodes and dantrolene stock/administration protocols from 2014-2019.
• Analysis of MH prevalence and dantrolene accessibility based on survey responses.

Main Results:

• Ten episodes of MH were reported across 238 departments between 2014-2019, yielding an estimated prevalence of 1:350,000.
• Dantrolene is available in only 20% of surveyed departments, with rapid administration (within 5 minutes) possible in just 16%.
• Less than half (44%) of units have established protocols for managing MH episodes.

Conclusions:

• The prevalence of MH in Poland appears lower than in other countries.
• Significant limitations exist in dantrolene accessibility and preparedness for MH crises in Poland.
• Improved reporting and dantrolene availability are crucial for managing MH in Poland.